Synthesis and biological evaluation of aryl azide derivatives of combretastatin a-4 as molecular probes for tubulin

Bioorganic and Medicinal Chemistry

Volumn 8, Issue 10, 2000, Pages 2417-2425

  Pinney, Kevin G ^a   Mejia, Maria P ^a   Villalobos, Victor M ^a   Rosenquist, Brent E ^a   Pettit, George R ^b   Verdier Pinard, Pascal ^c   Hamel, Ernest ^c  

^a BAYLOR UNIVERSITY   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

^c Screening Technologies Branch   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; COLCHICINE; COMBRETASTATIN A4; COMBRETASTATIN A4 DERIVATIVE; TUBULIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CYTOTOXICITY; DRUG ACTIVITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MICROTUBULE ASSEMBLY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHOTOAFFINITY LABELING;

ANTINEOPLASTIC AGENTS; AZIDES; MODELS, STRUCTURAL; MOLECULAR PROBES; STILBENES; TEMPERATURE; TUBULIN;

EID: 0033811815     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0896(00)00176-0     Document Type: Article

References (53)

1. Lodish, H.; Baltimore, D.; Berk, A.; Zipursky, S. L.; Matsudaira, P.; Darnell, J. Scientific American Books; Molecular Cell Biology, 3rd ed.; 1995, p. 1051.
2. Oakley B.R., Oakley C.E. Scientific American. 2:1995;58.
3. Ludueña R.F., Banerjee A., Khan I.A. Curr. Opin. in Cell Biol. 4:1992;53.
4. Nogales E., Wolf S.G., Downing K.H. Nature. 391:1998;199.
5. Joshi H.C. Curr. Opin. in Cell Biol. 10:1998;35.
6. Hamel E. Med. Chem. Rev. 16:1996;207.
7. Kingston D.G.I., Samaranayake G., Ivey C.A. J. Nat. Prod. 53:1990;1.
8. Nicolaou K.C., Winssinger N., Pastor J., Ninkovic S., Sarabia F., He Y., Vourloumis D., Yang Z., Li T., Giannakakou P., Hamel E. Nature. 387:1997;268.
9. Owellen R.J., Hartke C.A., Kickerson R.M., Hains F.O. Cancer Res. 36:1976;1499.
10. Lin C.M., Ho H.H., Pettit G.R., Hamel E. Biochemistry. 28:1989;6984.
11. Pettit G.R., Cragg G.M., Singh S.B. J. Nat. Prod. 50:1987;386.
12. Pettit G.R., Singh S.B., Cragg G.M. J. Org. Chem. 50:1985;3404.
13. Pettit G.R., Cragg G.M., Herald D.L., Schmidt J.M., Lohavanijaya P. Can. J. Chem. 60:1982;1374.
14. Chaplin D.J., Pettit G.R., Hill S.A. Anticancer Res. 19:1999;189.
15. Pettit G.R., Kamano Y., Herald C.L., Tuinman A.A., Boettner F.E., Kizu H., Schmidt J.M., Baczynskyj L., Tomer K.B., Bontems R.J. J. Am. Chem. Soc. 109:1987;6883.
16. Pettit G.R., Srirangam J.K., Barkoczy J., Williams M.D., Boyd M.R., Hamel E., Pettit R.K., Hogan F., Bai R., Chapuis J.C., McAllister S.C., Schmidt J.M. Anti-Cancer Drug Des. 13:1998;243.
17. Rao S., Horwitz S.B., Ringel I. J. Natl. Cancer Inst. 84:1992;785.
18. Staretz M.E., Hastie S.B. J. Org. Chem. 58:1993;1589.
19. Hahn K.M., Hastie S.B., Sundberg R.J. Photochem. Photobiol. 55:1992;17.
20. Uppuluri S., Knipling L., Sackett D., Wolff J. Proc. Natl. Acad. Sci. USA. 90:1993;11598.
21. Floyd L.J., Barnes L.D., Williams R.F. Biochemistry. 28:1989;8515.
22. Bai R., Pei X.-F., Boye O., Getahun Z., Grover S., Bekisz J., Nguyen N.Y., Brossi A., Hamel E. J. Biol. Chem. 271:1996;12639.
23. Olszewski J.D., Marshalla M., Sabat M., Sundberg R.J. J. Org. Chem. 59:1994;4285.
24. Rao S., He L., Chakravarty S., Ojima I., Orr G.A., Horwitz S.B. J. Biol. Chem. 274:1999;37990.
25. Rao S., Orr G.A., Chaudhary A.G., Kingston D.G.I., Horwitz S.B. J. Biol. Chem. 270:1995;20235.
26. Rao S., Krauss N.E., Heerding J.M., Swindell C.S., Ringel I., Orr G.A., Horwitz S.B. J. Biol. Chem. 269:1994;3132.
27. Pettit G.R., Singh S.B., Boyd M.R., Hamel E., Pettit R.K., Schmidt J.M., Hogan F. J. Med. Chem. 38:1995;1666.
28. Dark G.G., Hill S.A., Prise V.E., Tozer G.M., Pettit G.R., Chaplin D.J. Cancer Res. 57:1997;1829.
29. Cushman M., Nagarathnam D., Gopal D., Chakraborti A.K., Lin C.M., Hamel E. J. Med. Chem. 34:1991;2579.
30. Lin C.M., Singh S.B., Chu P.S., Dempcy R.O., Schmidt J.M., Pettit G.R., Hamel E. Mol. Pharmacol. 34:1988;200.
31. Jonnalagadda S.S., ter Haar E., Hamel E., Lin C.M., Magarian R.A., Day B.D. Bioorg. Med. Chem. 5:1997;715.
32. Rustin, G. J. S.; Galbraith, S.; Taylor, J.; Maxwell, R.; Tozer, G.; Baddely, H.; Wison, V.; Price, V.; Assessment of Selective Targeting Tumour Vasculature in Phase I Trial of Combretastatin A4 Phosphate (CA4P), Abstract from Conference entitled: Biological Basis for Antiangiogenic Therapy, Milan, Italy, 1999.
33. Iyer S., Chaplin D.J., Rosenthal D.S., Boulares A.H., Li L.-Y., Smulson M.E. Cancer Res. 8:1998;4510.
34. Pettit G.R., Rhodes M.R. Anti-Cancer Drug Des. 13:1998;183.
35. Tozer G.M., Prise V.E., Wilson J., Locke R.J., Vojnovic B., Stratford M.R.L., Dennis M.F., Chaplin D.J. Cancer Res. 59:1999;1626.
36. Li L., Rojiani A., Siemann D.W. Int. J. Radiat. Oncol., Biol., Phys. 42:1998;899.
37. Maxwell R.J., Pharm B., Nielsen F.U., Breidahl T., Stodkilde-Jorgensen H., Horsman M.R. Int. J. Radiat. Oncol., Biol., Phys. 42:1998;891.
38. Beauregard D.A., Thelwall P.E., Chaplin D.J., Hill S.A., Adams G.E., Brindle K.M. Br. J. Cancer. 77:1998;1761.
39. Pettit G.R., Toki B., Herald D.L., Verdier-Pinard P., Boyd M.R., Hamel E., Pettit R.K. J. Med. Chem. 41:1998;1688.
40. Aleksandrzak K., McGown A.T., Hadfield J.A. Anti-Cancer Drugs. 9:1998;545.
41. Li L., Wang H.K., Kuo S.C., Wu T.S., Mauger A., Lin C.M., Hamel E., Lee K.H. J. Med. Chem. 37:1994;3400.
42. Hamel E., Lin C.M., Flynn E., D'Amato R.J. Biochemistry. 35:1996;1304.
43. Gastpar R., Goldbrunner M., Marko D., von Angerer E. J. Med. Chem. 41:1998;4965.
44. Yoshimatsu K., Yamaguchi A., Yoshino H., Koyanagi N., Kitoh K. Cancer Res. 57:1997;3208.
45. Pinney K.G., Bounds A.D., Dingeman K.M., Mocharla V.P., Pettit G.R., Bai R., Hamel E. Bioorg. Med. Chem. Lett. 9:1999;1081.
46. Jiang J.D., Wang Y., Roboz J., Straunchen J., Holland J.F., Bekesi J.G. Cancer Res. 58:1998;2126.
47. Ohsumi K., Nakagawa R., Fukuda Y., Hatanaka T., Morinaga Y., Nihei Y., Ohishi K., Suga Y., Akiyama Y., Tsuji T. J. Med. Chem. 41:1998;3022.
48. Waldeck D.H. Chem. Rev. 415:1991.
49. Pettit G.R., Singh S.B. Can. J. Chem. 65:1987;2390.
50. Mullica D.F., Pinney K.G., Mejia P., Rosenquist B.E., Sappenfield E.L. Acta Cryst. Sec. C. C54:1998;695.
51. Initial cytotoxicity studies were carried out in the laboratory of Professor George R. Pettit (Cancer Research Institute, Arizona State University) using the NCI experimental protocols as delineated in ref 52.
52. Boyd M.R., Paull K.D. Drug Dev. Res. 34:1995;91.
53. Verdier-Pinard P., Lai J.-Y., Yoo H.-D., Yu J., Marquez B., Nagle D.G., Nambu M., White J.D., Falck J.R., Gerwick W.H., Day B.W., Hamel E. Mol. Pharmacol. 53:1998;62.